Lunit gets court approval for Volpara acquisition in New Zealand

New Zealand high court makes first-phase approval on Volpara acquisition plan, process expected to be finalized in May

Lunit gets court approval for Volpara acquisition in New Zealand
Yena Kim 1
Mar 14, 2024 (Gmt+09:00) yena@hankyung.com
Artificial intelligence

South Korean medical AI company Lunit announced on Thursday that it received the first approval from the High Court of New Zealand for its plan to acquire New Zealand-based AI breast cancer diagnostics solutions company Volpara Health Technologies.

According to Lunit, the acquisition approval process of the New Zealand court consists of two main steps.

The first step is the approval of the shareholders' meeting and the sale vote, and the second is to review the validity and effectiveness of the meeting results.

Following approval for the acquisition investment from the New Zealand financial authorities last month, Volpara will hold a shareholders meeting on April 12. 

In December last year, Lunit signed a deal to acquire 100% of Volpara's shares for $193.1 million. 

Volpara was Established in 2009 in Wellington. It has specialized in breast cancer diagnostic AI platforms. Its products are used in more than 2,000 medical institutions, accounting for a third of the breast imaging screening facilities in the US. 

"Volpara will contribute to Lunit's bid to build a super AI platform and secure sales in the United States," CEO of Lunit Suh Beom-Seok said. "We expect to complete the acquisition by May."

Write to Yena Kim at yena@hankyung.com

Lunit to supply AI image analysis solutions to Samsung Electronics

Lunit to supply AI image analysis solutions to Samsung Electronics

Lunit Insight CXR South Korean medical AI company Lunit has secured a significant partnership with tech giant Samsung Electronics Co., signing a three-year, $1.86 million contract to supply two of its cutting-edge AI solutions. This deal represents a substantial 17.7% of Lunit's 2022 revenue, s

Lunit acquires NZ-based AI diagnostics firm Volpara

Lunit acquires NZ-based AI diagnostics firm Volpara

South Korean medical AI company Lunit announced on Thursday that it will acquire New Zealand-based AI breast cancer diagnostics solutions company Volpara Health Technologies for $193.07 million.Under the deal, Volpara is valued at AUD 1.15 per share. This is a 47.4% increase from its previous

Lunit selected as contractor for building medical AI platform in Singapore

Lunit selected as contractor for building medical AI platform in Singapore

Lunit's Insight CXR South Korean medical AI company Lunit announced on Friday that it has been selected as the final contractor in the bidding for the establishment of the medical AI platform "AimSG" by SYNAPSE, Singapore's state-owned healthtech agency, aimed at innovating public healthcare se

Lunit gets FDA approval for AI cancer diagnosis solution

Lunit gets FDA approval for AI cancer diagnosis solution

South Korean medical AI company Lunit said on Tuesday its Lunit Insight DBT, an AI imaging diagnosis solution aiding in breast cancer diagnosis, has secured 510(k) pre-market clearance from the US Food and Drug Administration (FDA).This marks Lunit's third FDA approval, joining its AI emergenc

Lunit participates in US gov't Cancer Moonshot

Lunit participates in US gov't Cancer Moonshot

South Korea's medical AI company Lunit announced on Friday it will participate in the US President Joe Biden's cancer-conquering project Cancer Moonshot.The company joins CancerX, a public-private partnership for Cancer Moonshot. CancerX introduced Lunit as the first case for cancer diagnosis